Piramal Pharma Ltd
Piramal Pharma's GHG Emissions Data Preview
In 2025, Piramal Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Piramal Pharma has also provided a category-level breakdown for 13 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. a | Copy restricted. Please purchase to unlock this data. a | 0000000 |
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
aVerified Sources Behind Piramal Pharma’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Piramal Pharma’s data sources below and access millions more through our Disclosure Search.
Insights into Piramal Pharma's Operational Emissions
In 2025, the total operational greenhouse gas (GHG) emissions of Piramal Pharma amounted to 140,753 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Piramal Pharma increased by 3.77%, suggesting that the company faced challenges in reducing its emissions from its core operations. a
Piramal Pharma's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Piramal Pharma's Scope 1 emissions?
In 2025, the total Scope 1 emissions of Piramal Pharma were 61,351 metric tons of CO₂ equivalent (tCO₂e). a
Has Piramal Pharma reduced its Scope 1 emissions over time?
Since 2021, Piramal Pharma's Scope 1 emissions have increased by 48.21%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2024), Piramal Pharma's Scope 1 emissions increased by 9.11%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are Piramal Pharma's Scope 2 emissions?
In 2025, Piramal Pharma reported Scope 2 greenhouse gas (GHG) emissions of 66,098 tCO₂e using the market-based method and 79,402 tCO₂e using the location-based method. a
Has Piramal Pharma reduced its Scope 2 emissions over time?
Compared to the previous year (2024), Piramal Pharma's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Piramal Pharma 's emissions have plateaued with no significant change in its energy consumption footprint. a
What methodology does Piramal Pharma use for Scope 2 reporting?
In 2025, Piramal Pharma reported its Scope 2 emissions using the market-based method and using the location-based method. a
Piramal Pharma's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
- Total Scope 2 (Unspecified Calculation Method)
Insights into Piramal Pharma's Value Chain Emissions
In 2025, Piramal Pharma reported 491,081 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2025 disclosure of Piramal Pharma includes a breakdown across 13 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
Piramal Pharma's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Piramal Pharma's Scope 3 emissions?
In 2025, Piramal Pharma reported total Scope 3 emissions of 491,081 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 74.82% of these emissions originated from upstream activities such as purchased goods and capital goods, while 25.18% came from downstream activities like product use, distribution, and end-of-life treatment. a
Compared to the previous year (2024), Piramal Pharma's Scope 3 emissions remained relatively stable, indicating that Piramal Pharma 's emissions have plateaued with no significant change in its value chain footprint. a
What categories of Scope 3 emissions does Piramal Pharma disclose?
In 2025, Piramal Pharma reported emissions for 13 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of Piramal Pharma's Scope 3 emissions?
In 2025, the largest contributors to Piramal Pharma's Scope 3 emissions were: a
- Purchased Goods and Services (Cat. 1): 213,221 tCO₂e (43.42%)
- Use of Sold Products (Cat. 11): 114,359 tCO₂e (23.29%)
- Upstream Transportation and Distribution (Cat. 4): 88,273 tCO₂e (17.98%)
Piramal Pharma's Scope 3 Emissions by Categories
Insights into Piramal Pharma’s GHG Emissions Intensity Compared to Industry Peers
In 2025, Piramal Pharma reported Scope 1 greenhouse gas (GHG) emissions of 61,351 tCO₂e and total revenues of USD 1,061 millions. This translates into an emissions intensity of 57.85 tCO₂e per millions USD. a
Piramal Pharma's Scope 1 Emissions Intensity Compared to Peers
How does Piramal Pharma's GHG emissions intensity compare to its peers?
In 2025, Piramal Pharma reported a Scope 1 emissions intensity of 57.85 tCO₂e per millions USD. Compared to the peer group median of 24.05 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a
Where does Piramal Pharma rank on GHG emissions intensity within its industry?
In 2025, Piramal Pharma ranked 17 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
Piramal Pharma is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a
Insights into Piramal Pharma's Total Carbon Footprint
In 2025, Piramal Pharma reported a total carbon footprint of 631,834 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 0.55% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output. a
The largest contributor to Piramal Pharma's total carbon footprint was Scope 3 emissions, accounting for 77.72% of the company's total carbon footprint, followed by Scope 2 emissions at 12.57%. a